Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 Alone or in Combination With Lenalidomide in Non-Hodgkin Lymphoma
NCT04903197Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jan 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of ianalumab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 2 more (4 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events at 4 years and 2 more. Started Jan 2022; status: terminated.
02
Drugs
ianalumab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04903197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903197.